Market Signal Briefing

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Maywood Acquisition Corp. (NASDAQ: MAYA) related to its merger with GOWell Technology Limited. Upon completion of the proposed transaction, Maywood shareholders will receive shares in the newly combined company based on an exchange ratio. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/maywood-acquisition-corp/ https://monteverdelaw.com/case/soho-house-co-inc/ https://monteverdelaw.com/case/wideopenwest-inc-2/ https://monteverdelaw.com/case/sketchers-u-s-a-inc/ https://monteverdelaw.com/case/aimei-health-technology-co-ltd/ https://monteverdelaw.com/case/gms-inc/ . It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court?
When was the last time you recovered money for shareholders?
What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Matthew Quinn

Good morning, and on behalf of the Board, I would like to welcome you to the 2025 Annual General Meeting of Shareholders of Bravura Solutions Limited. This year's meeting is also being held online through a virtual meeting platform provided by MUFG, and all attendees are able to listen to a live webcast of the meeting. Members and proxies will have the ability to ask questions in person, online or through a conference call and submit votes either in person or online. It now being 10:00 AM and there being a quorum present, I declare the 2025 AGM of Bravura Solutions open.

I am Matthew Quinn, the Chair of Bravura Solutions and joining the meeting today is the Interim CEO, Shezad Okhai; other directors, Russell Baskerville, Charles Crouchman, Sarah Adam-Gedge, Damien Leonard, Dexter Salna, and our Company Secretary, Melissa Jones. Graham Leonard from our auditor, Ernst & Young, is also in attendance.

I'll start today's proceedings by making some brief remarks, and we'll then invite Interim CEO, Shezad Okhai, to address the meeting before we move on to the formal business.

FY '25 was a significant and successful year for the company. We improved on all financial metrics and returned significant amount of cash to shareholders through capital returns and dividends. The management team performed extremely well in delivering these results, and I would like to thank Andrew Russell, who stepped down as CEO in April for leading the team through his period. I'm pleased to report that our new CEO, Colin Greenhill, will join us on 1 January 2026, and I'm confident he will lead the company to further success.

SummaryNova Minerals is transitioning from exploration to development, relying on capital raises with a limited cash runway and no commercial revenues yet.The Estelle Gold & Critical Minerals Project, especially the RPM and Korbel deposits, is central to NVA's future, with antimony adding strategic value.Securing a land use permit for an antimony refinery at Port MacKenzie marks a shift toward vertical integration and potential US defense sector involvement.Key catalysts include the Port MacKenzie permit, 2025 Estelle Pre-Feasibility Study, drilling results, and possible government support, making the next 6-12 months critical. TommyIX/iStock via Getty Images

Nova Minerals Limited (NASDAQ:NVA) is a junior mining company, which develops Estelle Gold & Antimony Project in Alaska - one of the biggest underdeveloped gold deposits in the region. The company is transitioning from exploration to developing stage and has a clear goal - to become gold

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

NEW YORK and NEW ORLEANS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI), if they purchased the Company’s securities between February 26, 2025 to August 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of C3 and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ai/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by October 21, 2025.

About the Lawsuit

C3 and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 8, 2025, the Company disclosed disappointing preliminary financial results for 1Q 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing its poor sales results and lowered guidance to “the reorganization with new leadership” as well as the health ailments of its Chief Executive Officer.

On this news, the price of C3’s shares fell from a closing price of $22.13 per share on August 8, 2025 to $16.47 per share on August 11, 2025, a decline of about 25.58%.  

The case is John Liggett Sr. v. C3.ai, Inc., et al., No. 25-cv-07129.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

The claim that JPMorgan Chase & Co. (NYSE:JPM) "fixed" silver prices has fueled heated debates among retail investors. Here's a timely look at the facts behind the controversy as silver hits new all-time highs. 

Shares of the SLV ETF are soaring. See the details here. 
The conspiracy theory that gained traction in online forums, such as 4chan and Reddit's r/WallStreetBets, paints a picture of the nation's largest bank secretly controlling silver's price — however, the truth is far more complicated. 

Read Next: USA Rare Earth, Critical Metals Stocks Explode—JPMorgan Adds Fuel To The Fire

Market Manipulation Between 2008 and 2016, JPMorgan and several of its traders did engage in illegal market manipulation involving precious metals, including silver — but not in the way many online theories suggest.

Benzinga reached out to JPMorgan for comment, but did not receive an immediate response. 

SpoofingAfter an investigation, several U.S. regulators — including the Department of Justice (DOJ), the Securities Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) — found that some JPMorgan traders had engaged in a practice known as "spoofing" from 2008 to 2016, where they placed large orders for silver, gold and other metals futures they didn’t intend to execute. 

The intent was to create false impressions of demand or supply, tricking other traders and influencing the market price for short-term profit. 

This form of manipulation is illegal under U.S. trading laws, and several of the bank's traders were sentenced to prison for participating in the scheme.

It was not a coordinated attempt to fix silver prices at a particular level — unlike the historical "London Gold Fix" or other classic price-fixing agreements. Instead, it was a series of deceptive trades designed to move prices momentarily, allowing traders to profit from short-term fluctuations. 

Read Next: Rigetti, D-Wave, IonQ Could Get JPMorgan’s Support—Quantum Stocks Take Off

Not Price-Fixing Regulators found that these spoofing activities did distort the markets, but they did not conclude that JPMorgan set or maintained a specific silver price over time.

In 2020, JPMorgan Chase admitted to committing wire fraud in connection with: (1) unlawful trading in the markets for precious metals futures contracts; and (2) unlawful trading in the markets for U.S. Treasury futures contracts and in the secondary (cash) market for U.S. Treasury notes and bonds.  

The nation's largest bank also agreed to pay nearly $1 billion in fines to settle the investigations. 

Conspiracy TheoriesThe gap between the legal reality and the online conspiracy arose largely from public frustration and distrust of major banks after the 2008 financial crisis. Communities such as r/WallStreetBets and r/Silverbugs — known for their suspicion of Wall Street institutions — interpreted JPMorgan's massive position in silver and the record fine as evidence of a broader plot to suppress silver's value. 

The theories flourished on social media, especially during moments when silver prices stagnated despite inflationary fears or heavy retail buying.

Read Next: Retail Investors’ Top Stocks With Earnings This Week: Fastenal, ASML, TSMC And More

In reality, JPMorgan's wrongdoing involved unethical and illegal manipulation for trader profits, not a grand plan to keep silver undervalued. 

The billion-dollar fine and criminal convictions show that regulators took the misconduct seriously. 

But the notion that the bank systematically "fixed" or controlled silver prices to suppress investors is largely a myth rooted in mistrust rather than fact.

Silver Stocks and ETFsSilver surged in October to new all-time highs above $51 per ounce, surpassing the previous highs set in January 1980 (about $49.45 per ounce) and 2011 (near $49 per ounce). 

The historic rally has even seen silver briefly trade above $52.50 and $53 in London, eclipsing all prior benchmarks. 

The silver rally has also led to significant attention toward silver-related equities and ETFs, like the iShares Silver Trust (NYSE:SLV), which tracks the spot price of silver. 

Investors can also consider the Global X Silver Miners ETF (NYSE:SIL) which provides access to leading mining companies like Wheaton Precious Metals Corp. (NYSE:WPM) and Pan American Silver Corp. (NYSE:PAAS). 

Read Next: 

Quantum Stock Rally Leaves Shkreli’s Short ‘Pretty F***n’ Far From Okay’
Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

LVMH Moët Hennessy - Louis Vuitton, Société Européenne (NEOE:LV:CA) Q3 2025 Sales Call October 14, 2025 12:00 PM EDT

Company Participants

Cecile Cabanis - Chief Financial Officer
Rodolphe Ozun

Conference Call Participants

Zuzanna Pusz - UBS Investment Bank, Research Division
Antoine Belge - BNP Paribas Exane, Research Division
Erwan Rambourg - HSBC Global Investment Research
Thomas Chauvet - Citigroup Inc., Research Division
Edouard Aubin - Morgan Stanley, Research Division
Carole Madjo - Barclays Bank PLC, Research Division
Oliver Chen - TD Cowen, Research Division
Ashley Wallace - BofA Securities, Research Division
Piral Dadhania - RBC Capital Markets, Research Division
Chris Gao - CLSA Limited, Research Division

Presentation

Cecile Cabanis
Chief Financial Officer

Ladies and gentlemen, good afternoon. I hope you are well. I'm here with Rodolphe Ozun, who is our Head of Investor Relations. And together, we are very pleased to welcome you on our third quarter sales call. As usual, I will start with the highlights of the quarter, then Rodolphe will take you through the details of the division. I will conclude, and then we'll be happy to answer your questions. Before we start, I kindly ask you to read the safe harbor statement on Page 2 of your presentation before I move to Page 3 and start the presentation.

LVMH showed good resilience in the first 9 months of 2025 with improved trends in Q3 across all business groups. Fashion and Leather Goods, in particular, benefited from solid local demand in its key nationalities with Mainland China turning positive in Q3, solid growth in the U.S., which improved sequentially compared to Q2 and positive growth with Europeans in line with previous quarter.

The euro strength against key currencies generated a highly negative minus 5% impact in Q3 and currencies also remained a strong headwind to offshore demand in Europe and in Japan. Finally, all divisions continue to innovate and

Recommended For You

Amazon logo is seen in this illustration taken February 11, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

Oct 14 (Reuters) - Billionaire philanthropist MacKenzie Scott has reduced the size of her stake in Amazon.com

(AMZN.O), opens new tab by 42% since last year, Bloomberg News reported on Tuesday, citing a regulatory filing.

Scott, the former wife of Amazon founder Jeff Bezos, holds 81.1 million shares in the company, according to the latest disclosure dated September 30, down 58 million from a year ago, according to the news report.

Sign up here.

Based on Amazon's closing price on Tuesday, the reduction is worth $12.55 billion.

Reuters could not independently confirm the filing.

A regulatory filing made with the U.S. Securities and Exchange Commission in Bezos' name said he beneficially owned more than 964 million Amazon shares as of September 30, including 81.1 million shares over which Bezos exercises sole voting authority.

Amazon did not immediately respond to a Reuters request for comment.

As part of the terms of their divorce in 2019, Scott received a 4% stake in Amazon worth $36 billion from Bezos.

She has donated more than $19.25 billion to more than 2,450 non-profit teams, according to her Yield Giving website.

Reporting by Juby Babu in Mexico City; Editing by Pooja Desai

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Johnson & Johnson CFO and Executive Vice President Joe Wolk addresses the decision to spin off its orthopedics business, explains its innovations and more on ‘The Claman Countdown.'

Salesforce Founder, Chair, and CEO Marc Benioff joins 'Mad Money' host Jim Cramer to talk its Agentforce software, partnerships with AI companies, its investments in San Francisco, and much more.

By

PYMNTS
 | 
October 14, 2025

 | 

A little over four months after the removal of an asset cap that had been imposed by the Federal Reserve, Wells Fargo aims to shift the conversation from the improvements it made to earn that achievement to the work it has done to improve growth and returns.

“Wells Fargo, without the regulatory constraints and with the changes we have made, is a significantly more attractive company than what we were several years ago, and we believe this positions us for continued higher growth and returns,” Wells Fargo Chairman and CEO Charlie Scharf said Tuesday (Oct. 14) during the bank’s quarterly earnings call.

The asset cap that was removed by the Federal Reserve on June 3 was imposed in February 2018 as part of an enforcement action after a scandal that included Wells Fargo opening accounts without customer permission. The asset cap prevented the bank from growing its assets beyond its 2017 level until it addressed “widespread consumer abuses.”

While Wells Fargo enhanced its risk and control infrastructure to have 13 consent orders terminated since 2019, it has also made “substantial progress” in other areas during that period of time and is “a different company than we were five years ago,” the bank said in a presentation released Tuesday.

Wells Fargo has simplified its business by selling or exiting 12 businesses to focus on its core franchise; reduced expenses; and invested in people, technology and products to improve its capabilities and offerings, according to the presentation.

Looking ahead, the bank sees opportunities to grow revenue through the scale of its franchise and the breadth and quality of its products and capabilities; continue to boost its efficiency; and invest in businesses with higher returns, such as credit card, wealth management, and corporate and investment banking, per the presentation.

Advertisement: Scroll to Continue

Scharf said during Tuesday’s earnings call that Wells Fargo now aspires to be the top U.S. consumer and small business bank and wealth manager, the top U.S. bank to businesses of all sizes, and a top five U.S. investment bank.

“We expect all of our businesses to eventually generate returns and growth equal to our best competitors, while continuing to invest for the longer term,” Scharf added.

According to the presentation, Wells Fargo is currently ranked No. 3 in deposit share in consumer banking and lending, No. 3 as financial advisors among large bank peers, No. 4 in wealth client assets, No. 2 in U.S. corporate and investment loans, No. 6 in U.S. investment banking market share, No. 2 in bank commercial real estate loan portfolio, and No. 1 left lead arranger for middle market and leveraged loans.

“We have the scale necessary in all of these businesses today,” Scharf said during the call. “We have a strong and disciplined management team that has proven it can execute on our priorities. And with the regulatory constraints lifted, we have more degrees of freedom to grow and achieve our goals.”

Decades of Cross-Cloud Expertise Bolstered by Global Scale, Promising Enhanced Project Support and Breakthrough Personalized Experiences

, /PRNewswire/ -- ListEngage has entered into an agreement to join Tata Consultancy Services (TCS). The acquisition became public on October 9, 2025, with TCS approving a 100% stake in ListEngage for $72.8 million. ListEngage is a Salesforce consultancy focused on enabling emerging technologies and digital transformation with a keen focus on Marketing Cloud, Data Cloud, Agentforce, and Salesforce CRM solutioning.

The fully remote Summit Salesforce partner, ListEngage, sees this acquisition as a testament to the longtime company value proposition of placing expertise, growth, and culture above all else. ListEngage Founder and CEO, Altaf Shaikh, emphasized this philosophy, stating, "I've always said, talent over location, and culture over talent." ListEngage customers can expect greater scale for project support and more innovation than ever before, said Altaf Shaikh.

"ListEngage complements TCS' existing capabilities in customer experience and digital transformation. With this new team, and ListEngage's strong market coverage, we expect to scale delivery and unlock new efficiencies through our global delivery model. TCS remains fully committed to supporting existing customers, ensuring continuity and excellence in service delivery," said Vikram Karakoti, Tata Consultancy Services, Global Head, Enterprise Solutions.

ListEngage adds more than 400 Salesforce certifications across more than 100 employees. ListEngage's deep expertise in AI-led marketing automation, cross-cloud data integration, and personalized marketing created a fantastic opportunity for a growth platform.

"Joining TCS means a lot of great things, but most of all - it means we're going to have a greater capacity to serve our customers," said Bryan da Frota, ListEngage COO.

ListEngage will now join TCS's global workforce of over 600,000 employees. Bryan da Frota also noted the complementary cultures, remarking, "Our ability to service companies just got multiplied and bolstered by a company that not only has the incredible capabilities, but incredible culture to match our own." This strategic acquisition bolsters TCS's focus on AI and intelligent automation.

"By bringing together TCS's global scale with ListEngage's Salesforce and AI expertise, we're creating a powerhouse that will redefine how enterprises harness data, cloud, and AI to drive meaningful business outcomes," said Altaf Shaikh.

This acquisition "opens a world of opportunity to scale and innovate even more with AI," within the Salesforce ecosystem, according to Pratik Desai, ListEngage Head of Applied AI. Desai further expressed his excitement for the future, stating, "I've been in the Salesforce ecosystem for more than 10 years, and I can honestly say I've never been more excited for what's next."

The enhanced capacity is crucial for supporting cutting-edge technologies like Agentforce, Salesforce's digital labor platform. ListEngage is already recognized as a critical partner for identifying and developing specific use cases for joint customers across industries, helping to ensure tailored and effective AI solutions for scaling digital labor. Through this acquisition, ListEngage now has greater scale. "This is like adding rocket fuel to our team, leading the charge on emerging technologies, innovations, and AI," said Pratik Desai.

ListEngage has been on a growth trajectory since its inception in 2003, continuously increasing its practice size and disciplines across the ecosystem of Salesforce solutions. ListEngage Founder & CEO, Altaf Shaikh, takes pride in having built a company that scales across the clouds, including Salesforce Marketing Cloud, Data Cloud, Agentforce, CRM, and beyond.

"Our people are what make our company great. They're how we've gotten this far - coming from a small group of five in 2003, to where we are now, it's been an amazing journey. This is going to be our best chapter yet," said Altaf Shaikh.

For more information about ListEngage, visit www.listengage.com

ListEngage's Salesforce-certified and accredited experts guide your business to get the most out of AI-led marketing automation, cross-cloud data integration, and personalized marketing. With top-tier expertise across Marketing Cloud, Data Cloud, Agentforce and CRM, embark on your Salesforce Journey with a cross-cloud consulting partner who's done it all, from platform onboarding to large digital transformations and platform migration. As a Salesforce Ventures-backed, Summit status partner, customer success is at the heart of everything ListEngage accomplishes. ListEngage has supported 5,000+ successful projects and over 3,000 happy customers since inception in 2003.

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) is a digital transformation and technology partner of choice for industry-leading organizations worldwide. Since its inception in 1968, TCS has upheld the highest standards of innovation, engineering excellence and customer service.

Rooted in the heritage of the Tata Group, TCS is focused on creating long term value for its clients, its investors, its employees, and the community at large. With a highly skilled workforce spread across 55 countries and 202 service delivery centers across the world, the company has been recognized as a top employer in six continents. With the ability to rapidly apply and scale new technologies, the company has built long term partnerships with its clients – helping them emerge as perpetually adaptive enterprises. Many of these relationships have endured into decades and navigated every technology cycle, from mainframes in the 1970s to Artificial Intelligence today.

TCS sponsors 14 of the world's most prestigious marathons and endurance events, including the TCS New York City Marathon, TCS London Marathon and TCS Sydney Marathon with a focus on promoting health, sustainability, and community empowerment.

TCS generated consolidated revenues of over US $30 billion in the fiscal year ended March 31, 2025. For more information, visit www.tcs.com

SOURCE ListEngage

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Investors should monitor Nvidia's competitive landscape closely.

Nvidia (NVDA -4.33%) continues to be a key enabler of the global artificial intelligence (AI) infrastructure buildout, with over 94% share of the discrete GPU market in the second quarter of 2025. Its Blackwell architecture chips, Compute Unified Device Architecture (CUDA) software stack, and AI-optimized networking solutions together form a formidable competitive moat.

The company's commitment to innovation -- releasing new hardware architectures annually while maintaining backward compatibility -- has increased customer loyalty. Unsurprisingly, demand for the company's GPUs from hyperscalers and enterprise AI giants has consistently outpaced available supply.

Image source: Getty Images.

Nvidia's dominance, however, may face serious challenges in 2026. Increasing competitive and geopolitical pressures, along with a rising focus on cost-effectiveness, may affect the company's topline and bottom-line growth prospects in the coming year. Here's how I believe these problems could evolve in 2026.

Competitive pressures
The biggest challenge for Nvidia is the rapid emergence of alternatives to its GPUs, both from competitors offering chips with superior price performance and large clients developing proprietary silicon for specialized AI workloads.

While still far behind in the discrete GPU market share, competitor Advanced Micro Devices (AMD 0.80%) is gearing up for the launch of Instinct MI450 series GPUs in 2026. These GPUs are based on CDNA 5 architecture and are built using Taiwan Semiconductor Manufacturing's (also known as TSMC) advanced 2-nanometer process technology. The MI450 series is expected to emerge as direct competition not only to Nvidia's Hopper and Blackwell GPUs, but also to the upcoming Rubin architecture GPUs built on 3-nanometer process technology.

AMD's recent strategic partnership with OpenAI underlines the confidence in this new AI chip. According to this multi-year and multi-generation partnership, OpenAI will deploy 6 gigawatts of AMD Instinct GPUs. The first 1 gigawatt deployment based on MI450 GPUs will commence in the second half of 2026. With the deal positioning AMD as a core compute supplier for OpenAI's next-generation frontier models, AMD CEO Lisa Su expects to generate tens of billions of dollars in annual AI data-center revenue starting in 2027. AMD estimates this collaboration, along with other large customer deployments, could eventually generate over $100 billion in revenue in the next few years.

CEO Lisa Su also claimed that AMD's chiplet-based GPU architecture (a processor made of several small chips) offers substantial advantages in memory capacity and bandwidth, which can be crucial for inference workloads. As hyperscalers push for unified infrastructure that can handle both training and inference, AMD's upcoming MI450 GPUs are being designed to serve both workloads efficiently.

AMD's increasing technological prominence in the GPU market poses a significant challenge to Nvidia's supremacy.

Broadcom's custom application-specific integrated circuits (ASICs) and other accelerators are also being increasingly adopted at hyperscaler data centers. Major cloud players such as Meta Platforms, Microsoft, Amazon, and Alphabet have also developed custom silicon, which reduces their reliance on Nvidia. Alphabet's Tensor Processing Units (TPUs) and Amazon's Inferentia chips already deliver better performance at a lower cost in specific training and inferencing tasks. As more hyperscalers scale these in-house solutions and partner with other semiconductor players, it could adversely impact Nvidia's share of the AI compute spending.

Cost advantages
AMD's competitive pricing may soon become a key differentiator, especially since the target addressable market for AI accelerators is now projected to surpass $500 billion by 2028. AMD claims that its MI355 accelerator (from the MI350 series accelerators) has demonstrated matching or better performance than Nvidia's Blackwell architecture-based GB200 chips for specific key training and inference workloads. MI355 was also said to deliver performance matching to that of GB200 for specific other workloads at a lower cost and capacity.

According to Dell'Oro Group, global data center capex is estimated to reach $1.2 trillion by 2029. Hyperscalers are expected to account for nearly half of this spend. Faced with escalating infrastructure and energy costs, cloud giants are exploring lower-cost accelerators to reduce the total cost of ownership while ensuring high performance. In this backdrop, AMD's competitively priced Instinct accelerators could prove to be an appealing alternative for hyperscalers. This may even pressure Nvidia to take some pricing cuts to protect its market share.

Geopolitical and Supply Chain Pressures
Nvidia's excessive reliance on TSMC's foundries has exposed it to significant geopolitical and supply chain disruption risk, considering that Taiwan is just roughly 100 miles from mainland China. The escalating U.S.-China tensions have already negatively impacted the company's chip exports to China.

In July 2025, China's internet regulator, The Cyberspace Administration of China summoned Nvidia to explain the alleged security vulnerabilities in its H20 chips. Chinese authorities have also intensified customs inspections of Nvidia's AI chip imports, to reduce reliance on U.S. imports as of October 2025. According to Reuters, China's crackdown was initially focused on China-specific models like the H20 and RTX Pro 6000D. However, it has now been expanded to include all advanced semiconductor products that could fall under U.S. export restrictions. These events have negatively impacted the company's sales in the key Chinese market.

The heightened geopolitical tensions have also spurred countries around the world to focus on localizing the semiconductor supply chain. Several incentives are being offered to semiconductor manufacturers under the U.S. CHIPS Act and similar programs in Europe and Japan. TSMC, Samsung, and Intel are building new foundries in the U.S., Europe, and Asia.

While these foundries are not Nvidia's direct competitors, expansion of manufacturing capacity will help competitors such as AMD, Intel, and Broadcom, as well as hyperscalers designing custom AI silicon to scale production efficiently. This may erode Nvidia's supply advantage in the long run.

Premium valuation
Nvidia trades at a premium valuation of 28.5 times forward earnings. However, in the face of increasing adoption of open hardware ecosystems and alternative AI chips, the company may witness compression in valuation multiples. Coupled with potential margin compression and slower topline growth, these factors may weigh on the company's share prices in 2026.

While none of these risks are certain to materialize, investors should remain vigilant about market share shifts and cost-sensitive deployments across the AI landscape. These are tangible risks, and Nvidia has to navigate them carefully to sustain its growth trajectory beyond 2026.

Manali Pradhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Intel, Meta Platforms, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be featured in six Astellas-sponsored poster presentations during The Menopause Society 2025 Annual Meeting in Orlando, Florida, October 21-25. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.1,2

The presentations, which feature three Late Breaking Abstracts (LBA), will include two preliminary analyses from the OPTION-VMS study. These analyses evaluate, in a real-world setting, both the changes in the impact VMS among women beginning non-hormonal therapy (non-HT) for VMS and the effects on work productivity for women initiating non-HT to manage these symptoms. These results highlight Astellas' commitment to expanding clinical knowledge about VEOZAH beyond the pivotal trials to help improve the lives of all those impacted by VMS due to menopause.

Karla Martins, Executive Medical Director for Global Medical Affairs, Astellas
"Astellas is dedicated to expanding the clinical understanding of our medicines. We are pleased to share comprehensive data on fezolinetant at this year's TMS meeting. These results provide further evidence of the efficacy and safety of fezolinetant as a treatment option for moderate to severe VMS due to menopause."

Fezolinetant data to be presented as posters during the 2025 Annual Meeting of The Menopause Society include:

OPTION-VMS: Preliminary Analysis of a Phase IV Observational, Real-World Study of Non-hormonal Pharmacotherapies for Bothersome Menopause-Associated Vasomotor Symptoms [Abstract ID: 4380798 / Poster #: P-127, Genevieve Neal-Perry, Samuel Lederman, Shayna Mancuso, Arianne Schild, Michele Helbing, Aki Shiozawa, Karla Martins, Pauline Maki, Rebecca Thurston]
Preliminary Analysis of Work Productivity Outcomes in OPTION-VMS: A Phase IV Observational, Real-World Study of Non-hormonal Treatment for Bothersome Menopause-Associated Vasomotor Symptoms [Abstract ID: 4380913 / Poster #: P-108, Pauline Maki, Shayna Mancuso, Michele Helbing, Arianne Schild, Karla Martins, Genevieve Neal-Perry, Rebecca Thurston]
A Matching-Adjusted Indirect Comparison of Fezolinetant and Elinzanetant for the Treatment of Vasomotor Symptoms Due to Menopause [Abstract ID: 4343203/ Poster #: P-154, Maria Shapiro, Petra Stute, Antonia Morga, Ting-an Tai, Mayank Ajmera, Bogdan Muresan, Karla Martins, Yechu Hua, Angela Zhao, Jingyi Liu, Rossella Nappi]
Prior Treatment Patterns and Healthcare Resource Utilization of Individuals Who Received Fezolinetant Treatment: A Claims Database Analysis [Abstract ID: 4308801 / Poster #: P-38, Barbara DePree, Mayank Ajmera, Valery Walker, Hannah Clark, Di Zhao, Christina Steiger, Michele Helbing]
Vasomotor Symptoms Due to Menopause after Treatment Discontinuation in Phase 3 Fezolinetant SKYLIGHT Studies [Abstract ID: 4342174 / Poster #: P-128, Genevieve Neal-Perry, Petra Stute, Karla Martins, Arianne Schild, Xuegong Wang, Rossella Nappi]
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause in Participants with Medical Comorbidities: Pooled Analysis of Three 52-Week Phase 3 Studies (SKYLIGHT 1, 2, and 4) [Abstract ID: 4342237 / Poster #: P-158, Andrea Singer, Michele Helbing, Arianne Schild, Kaitlin Montagano, Karla Martins, Risa Kagan, Antonio Cano]

An additional poster presentation will highlight results from a survey to understand factors contributing to healthcare and treatment perceptions for menopause and related VMS among non-Hispanic/Latino black or African American women in the US.

Posters will be presented on Thursday, October 23, 6:15 – 7:15 PM.

About OPTION-VMS
OPTION-VMS (NCT06049797) is an ongoing Phase IV, longitudinal, observational, study on women aged 40-75 years with confirmed menopausal VMS who were prescribed a non-hormonal therapy (non-HT) for the treatment of bothersome VMS by their healthcare provider in a real-world setting. The primary objective of the study is to evaluate the change in VMS bother in women; additional outcomes include sleep quality, menopause-related quality of life, sexual health, mood and work productivity. A total of 998 women were enrolled at 50 sites in the U.S.

About the BRIGHT SKY™ Phase 3 Program
The BRIGHT SKY pivotal trials, SKYLIGHT 1™ (NCT04003155) and SKYLIGHT 2™ (NCT04003142), enrolled over 1,000 menopausal women with moderate to severe VMS. The trials are double-blinded, placebo-controlled for the first 12 weeks followed by a 40-week treatment extension period. Women were enrolled at over 180 sites within the U.S., Canada and Europe. SKYLIGHT 4™ (NCT04003389) is a 52-week double-blinded, placebo-controlled study designed to investigate the long-term safety of fezolinetant. For SKYLIGHT 4, over 1,800 menopausal women with VMS were enrolled at over 180 sites within the U.S., Canada and Europe.

About VEOZAH™ (fezolinetant)
VEOZAH (fezolinetant) is a nonhormonal neurokinin 3 (NK3) receptor antagonist indicated in the United States for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause. VEOZAH works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/ dynorphin (KNDy) neuron to modulate neuronal activity in the brain's temperature control center (the hypothalamus) to reduce the frequency and severity of moderate to severe VMS due to menopause 3,4,5

U.S. Important Safety Information

VEOZAH can cause serious side effects, including: 

Liver Problems. Your healthcare provider will do a blood test to check your liver before you start taking VEOZAH. Your healthcare provider will also do this blood test monthly for the first 3 months, at month 6, and month 9 after you start taking VEOZAH or if you have signs or symptoms that suggest liver problems. If your liver blood test values are elevated, your healthcare provider may advise you to stop treatment or request additional liver blood tests.

Stop VEOZAH right away and call your healthcare provider if you have the following signs or symptoms of liver problems: 

feeling more tired than you do usually
decreased appetite
nausea
vomiting
itching
yellowing of the eyes or skin (jaundice)
pale feces
dark urine
pain in the stomach (abdomen)

Do not use VEOZAH if you: 

have cirrhosis.
have severe kidney problems or kidney failure.
are taking certain medicines called CYP1A2 inhibitors. Ask your healthcare provider if you are not sure.

Before you use VEOZAH, tell your healthcare provider about all your medical conditions, including if you: 

have liver disease or problems.
have kidney problems.
have any medical conditions that may become worse while you are using VEOZAH.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEOZAH may affect the way other medicines work, and other medicines may affect how VEOZAH works.

The most common side effects of VEOZAH include: 

stomach (abdominal) pain
diarrhea
difficulty sleeping (insomnia)
back pain
hot flashes or hot flushes

These are not all the possible side effects of VEOZAH. Tell your healthcare provider if you have any side effect that bothers you or does not go away.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the full Prescribing Information and Patient Product Information for VEOZAH (fezolinetant).

About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

References:

1 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.

2 Jones RE, Lopez KH, eds. Human Reproductive Biology. 4th ed. Waltham, MA: Elsevier, 2014:120.

3 Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905.

4 Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27:382-392. 

5 Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderate levels of ovarian hormones throughout the menstrual cycle. Endocrinology. 2015;156:4214-4225. 

SOURCE Astellas Pharma Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Hilary Kramer looks at payment stocks; she likes Klarna (KLAR) because of its relationship with Amazon (AMZN), and Jefferson Capital (JCAP). In energy, she likes Oklo (OKLO), citing pressures on the grid.

As two of the most prominent asset managers, BlackRock (BLK - Free Report)  and Goldman Sachs (GS - Free Report)  helped highlight Tuesday’s Q3 earnings lineup after exceeding their quarterly expectations and hitting records in assets under management (AUM).

Notably, both firms are benefiting from strong inflows across asset classes and strategic positioning in high-growth areas like passive investing and digital finance.   

BlackRock shares were nicely up over +3% in today’s trading session, with BLK extending to year-to-date gains of +18% while Goldman Sachs stock dipped 2% on what appears to be some profit taking as GS is still up an impressive +37% YTD.

Image Source: Zacks Investment Research

BlackRock & Goldman Sachs Q3 ResultsPosting Q3 sales of $6.5 billion, BlackRock’s top line expanded 25% from $5.19 billion in the prior year quarter and topped estimates of $6.24 billion. BlackRock’s Q3 earnings were up nearly 1% to $11.55 per share, beating EPS expectations of $11.19 by 3%.

Pivoting to Goldman Sachs, Q3 sales of $15.18 billion stretched 19% from $12.69 billion a year ago and noticeably exceeded estimates of $14.14 billion by 7%. More impressive, Goldman Sachs' Q3 EPS climbed nearly 46% to $12.25 compared to $8.40 per share in the comparative quarter and beat expectations of $11.11 by 10%.

BlackRock & Goldman Sachs Record AUMRemaining the largest global asset manager, BlackRock’s AUM spiked 17% year over year to a record $13.5 trillion.

Placing among the top 10 largest asset managers globally, Goldman Sachs' AUM also hit a new peak of $3.45 trillion, rising 11% YoY.

BLK & GS Valuation ComparisonGoldman Sachs' valuation stands out at 16X forward earnings. In this regard, GS trades at a distinct discount to the benchmark S&P 500’s 25X forward earnings multiple, with BlackRock at 24X.

GS also trades near the preferred level of less than 2X forward sales, with BLK at 8X and trading at a premium to the S&P 500’s 5X.

Image Source: Zacks Investment Research

BLK & GS Dividend ComparisonOffering respectable dividends, Goldman Sachs' current yield of 2.03% edges BlackRock’s 1.8%. These yields top the S&P 500’s 1.11% average, although BlackRock’s slightly trails the broader Zacks financial sector’s 1.89%.

Image Source: Zacks Investment Research

Should Investors Buy BLK or GS Stock?Despite having the advantage in AUM, BlackRock stock pales in comparison to Goldman Sachs in many metrics. However, both of these prominent finance stocks have proven to be viable investments in the portfolio, and for now, they land a Zacks Rank #3 (Hold), respectively.

That said, a buy rating could certainly be on the way for Goldman Sachs, as earnings estimate revisions are likely to rise in the coming weeks, given its impressive Q3 EPS beat. 

Cadence Design Systems (CDNS - Free Report) closed the most recent trading day at $325.75, moving -1.95% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.16%. At the same time, the Dow added 0.44%, and the tech-heavy Nasdaq lost 0.76%.

Shares of the maker of hardware and software products for validating chip designs have depreciated by 5.49% over the course of the past month, underperforming the Computer and Technology sector's gain of 3.34%, and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Cadence Design Systems in its forthcoming earnings report. The company is scheduled to release its earnings on October 27, 2025. On that day, Cadence Design Systems is projected to report earnings of $1.79 per share, which would represent year-over-year growth of 9.15%. Our most recent consensus estimate is calling for quarterly revenue of $1.32 billion, up 8.96% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.91 per share and revenue of $5.25 billion, indicating changes of +15.75% and +13.06%, respectively, compared to the previous year.

Investors might also notice recent changes to analyst estimates for Cadence Design Systems. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Cadence Design Systems holds a Zacks Rank of #2 (Buy).

In terms of valuation, Cadence Design Systems is currently trading at a Forward P/E ratio of 48.11. This valuation marks a premium compared to its industry average Forward P/E of 27.49.

Also, we should mention that CDNS has a PEG ratio of 3.45. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Computer - Software was holding an average PEG ratio of 2.06 at yesterday's closing price.

The Computer - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 80, finds itself in the top 33% echelons of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

CyberArk (CYBR - Free Report) closed at $491.30 in the latest trading session, marking a -2.52% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.16%. On the other hand, the Dow registered a gain of 0.44%, and the technology-centric Nasdaq decreased by 0.76%.

Shares of the maker of software that detects attacks on privileged accounts witnessed a gain of 5.9% over the previous month, beating the performance of the Computer and Technology sector with its gain of 3.34%, and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of CyberArk in its forthcoming earnings report. On that day, CyberArk is projected to report earnings of $0.92 per share, which would represent a year-over-year decline of 2.13%. Alongside, our most recent consensus estimate is anticipating revenue of $327.05 million, indicating a 36.21% upward movement from the same quarter last year.

CYBR's full-year Zacks Consensus Estimates are calling for earnings of $3.86 per share and revenue of $1.33 billion. These results would represent year-over-year changes of +27.39% and +32.53%, respectively.

Any recent changes to analyst estimates for CyberArk should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 66.92% lower. CyberArk is currently a Zacks Rank #4 (Sell).

Digging into valuation, CyberArk currently has a Forward P/E ratio of 130.72. For comparison, its industry has an average Forward P/E of 70.9, which means CyberArk is trading at a premium to the group.

It is also worth noting that CYBR currently has a PEG ratio of 5.38. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Security industry was having an average PEG ratio of 2.82.

The Security industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 211, placing it within the bottom 15% of over 250 industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Albertsons Companies, Inc. (ACI - Free Report) reported $18.92 billion in revenue for the quarter ended August 2025, representing a year-over-year increase of 2%. EPS of $0.44 for the same period compares to $0.51 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $18.9 billion, representing a surprise of +0.1%. The company delivered an EPS surprise of +12.82%, with the consensus EPS estimate being $0.39.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Albertsons Companies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Same - Store Sales (Identical sales): 2.2% compared to the 2% average estimate based on five analysts.Number of stores at end of quarter: 2,257 versus 2,267 estimated by four analysts on average.Total Square Footage - Retail Square Feet: 112.5 million compared to the 112.93 million average estimate based on three analysts.Revenues- Fuel: $911.3 million versus $951.3 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.2% change.View all Key Company Metrics for Albertsons Companies here>>>

Shares of Albertsons Companies have returned -7.9% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Kroger (KR - Free Report) ended the recent trading session at $69.13, demonstrating a +2.98% change from the preceding day's closing price. This change outpaced the S&P 500's 0.16% loss on the day. On the other hand, the Dow registered a gain of 0.44%, and the technology-centric Nasdaq decreased by 0.76%.

Prior to today's trading, shares of the supermarket chain had lost 0.42% was narrower than the Retail-Wholesale sector's loss of 4.08% and lagged the S&P 500's gain of 1.14%.

Market participants will be closely following the financial results of Kroger in its upcoming release. In that report, analysts expect Kroger to post earnings of $1.04 per share. This would mark year-over-year growth of 6.12%. In the meantime, our current consensus estimate forecasts the revenue to be $34.31 billion, indicating a 2.02% growth compared to the corresponding quarter of the prior year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.79 per share and a revenue of $148.79 billion, indicating changes of +7.16% and +1.13%, respectively, from the former year.

Any recent changes to analyst estimates for Kroger should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.13% higher. Kroger presently features a Zacks Rank of #3 (Hold).

In terms of valuation, Kroger is presently being traded at a Forward P/E ratio of 14.03. This represents a discount compared to its industry average Forward P/E of 16.94.

Investors should also note that KR has a PEG ratio of 1.95 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. KR's industry had an average PEG ratio of 2.39 as of yesterday's close.

The Retail - Supermarkets industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Oscar Health, Inc. (OSCR - Free Report) ended the recent trading session at $20.69, demonstrating a +1.42% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

Shares of the company witnessed a gain of 8.92% over the previous month, beating the performance of the Finance sector with its loss of 1.81%, and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Oscar Health, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on November 6, 2025. In that report, analysts expect Oscar Health, Inc. to post earnings of -$0.55 per share. This would mark a year-over-year decline of 150%. Alongside, our most recent consensus estimate is anticipating revenue of $3.09 billion, indicating a 27.51% upward movement from the same quarter last year.

OSCR's full-year Zacks Consensus Estimates are calling for earnings of -$1.42 per share and revenue of $12.06 billion. These results would represent year-over-year changes of -1520% and +31.44%, respectively.

It is also important to note the recent changes to analyst estimates for Oscar Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Oscar Health, Inc. boasts a Zacks Rank of #3 (Hold).

The Insurance - Multi line industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

In the latest close session, Kraft Heinz (KHC - Free Report) was up +1.31% at $25.44. This change outpaced the S&P 500's 0.16% loss on the day. Meanwhile, the Dow experienced a rise of 0.44%, and the technology-dominated Nasdaq saw a decrease of 0.76%.

Prior to today's trading, shares of the processed food company with dual headquarters in Pittsburgh and Chicago had lost 2.03% was narrower than the Consumer Staples sector's loss of 3.79% and lagged the S&P 500's gain of 1.14%.

Analysts and investors alike will be keeping a close eye on the performance of Kraft Heinz in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2025. The company's upcoming EPS is projected at $0.57, signifying a 24.00% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $6.27 billion, down 1.79% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $2.57 per share and revenue of $25.25 billion, which would represent changes of -16.01% and -2.31%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Kraft Heinz. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.3% lower within the past month. Right now, Kraft Heinz possesses a Zacks Rank of #4 (Sell).

In the context of valuation, Kraft Heinz is at present trading with a Forward P/E ratio of 9.76. This denotes a discount relative to the industry average Forward P/E of 15.51.

It's also important to note that KHC currently trades at a PEG ratio of 2.94. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. KHC's industry had an average PEG ratio of 1.68 as of yesterday's close.

The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 195, which puts it in the bottom 22% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow KHC in the coming trading sessions, be sure to utilize Zacks.com.

Hyster-Yale (HY - Free Report) closed at $36.14 in the latest trading session, marking a +1.89% move from the prior day. This change outpaced the S&P 500's 0.16% loss on the day. Meanwhile, the Dow gained 0.44%, and the Nasdaq, a tech-heavy index, lost 0.76%.

Coming into today, shares of the maker of lift trucks and aftermarket parts had lost 1.47% in the past month. In that same time, the Industrial Products sector lost 0.75%, while the S&P 500 gained 1.14%.

The upcoming earnings release of Hyster-Yale will be of great interest to investors. On that day, Hyster-Yale is projected to report earnings of $0.03 per share, which would represent a year-over-year decline of 96.91%. In the meantime, our current consensus estimate forecasts the revenue to be $955.69 million, indicating a 5.95% decline compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates project earnings of $0.75 per share and a revenue of $3.77 billion, demonstrating changes of -91.65% and -12.59%, respectively, from the preceding year.

Investors should also take note of any recent adjustments to analyst estimates for Hyster-Yale. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Hyster-Yale possesses a Zacks Rank of #3 (Hold).

In terms of valuation, Hyster-Yale is presently being traded at a Forward P/E ratio of 47.29. This indicates a premium in contrast to its industry's Forward P/E of 19.57.

The Manufacturing - Construction and Mining industry is part of the Industrial Products sector. Currently, this industry holds a Zacks Industry Rank of 204, positioning it in the bottom 18% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Booz Allen Hamilton (BAH - Free Report) closed at $97.80 in the latest trading session, marking a +1.57% move from the prior day. This move outpaced the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

The defense contractor's shares have seen a decrease of 5.25% over the last month, not keeping up with the Business Services sector's loss of 3.78% and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Booz Allen Hamilton in its forthcoming earnings report. The company is scheduled to release its earnings on October 24, 2025. The company is forecasted to report an EPS of $1.51, showcasing a 16.57% downward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $2.99 billion, reflecting a 5.09% fall from the equivalent quarter last year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.33 per share and revenue of $12.13 billion. These totals would mark changes of -0.31% and +1.22%, respectively, from last year.

It is also important to note the recent changes to analyst estimates for Booz Allen Hamilton. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.47% lower. Booz Allen Hamilton presently features a Zacks Rank of #4 (Sell).

With respect to valuation, Booz Allen Hamilton is currently being traded at a Forward P/E ratio of 15.21. This valuation marks a discount compared to its industry average Forward P/E of 20.02.

Meanwhile, BAH's PEG ratio is currently 1.52. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Consulting Services stocks are, on average, holding a PEG ratio of 1.25 based on yesterday's closing prices.

The Consulting Services industry is part of the Business Services sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 32% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Vital Farms (VITL - Free Report) closed the most recent trading day at $41.98, moving +1.01% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

Heading into today, shares of the company had lost 11.69% over the past month, lagging the Consumer Staples sector's loss of 3.79% and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Vital Farms in its forthcoming earnings report. In that report, analysts expect Vital Farms to post earnings of $0.29 per share. This would mark year-over-year growth of 81.25%. In the meantime, our current consensus estimate forecasts the revenue to be $191.08 million, indicating a 31.78% growth compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $1.37 per share and revenue of $772.03 million, which would represent changes of +16.1% and +27.33%, respectively, from the prior year.

Investors should also take note of any recent adjustments to analyst estimates for Vital Farms. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.19% upward. Right now, Vital Farms possesses a Zacks Rank of #3 (Hold).

Looking at its valuation, Vital Farms is holding a Forward P/E ratio of 30.42. This indicates a premium in contrast to its industry's Forward P/E of 15.51.

The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry, currently bearing a Zacks Industry Rank of 195, finds itself in the bottom 22% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow VITL in the coming trading sessions, be sure to utilize Zacks.com.

In the latest close session, DaVita HealthCare (DVA - Free Report) was up +2.19% at $126.62. This move outpaced the S&P 500's daily loss of 0.16%. Meanwhile, the Dow experienced a rise of 0.44%, and the technology-dominated Nasdaq saw a decrease of 0.76%.

The stock of kidney dialysis provider has fallen by 5.38% in the past month, lagging the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.

Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2025. In that report, analysts expect DaVita HealthCare to post earnings of $3.29 per share. This would mark year-over-year growth of 27.03%. Meanwhile, our latest consensus estimate is calling for revenue of $3.4 billion, up 4.27% from the prior-year quarter.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $10.93 per share and revenue of $13.46 billion, indicating changes of +12.91% and +5.01%, respectively, compared to the previous year.

It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, DaVita HealthCare is carrying a Zacks Rank of #3 (Hold).

With respect to valuation, DaVita HealthCare is currently being traded at a Forward P/E ratio of 11.34. This denotes a discount relative to the industry average Forward P/E of 21.14.

It is also worth noting that DVA currently has a PEG ratio of 0.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.88 as trading concluded yesterday.

The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 36, this industry ranks in the top 15% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow DVA in the coming trading sessions, be sure to utilize Zacks.com.